Pharmafile Logo

IPF World Week

- PMLiVE

FDA sets June decision date for Tecentriq monotherapy in NSCLC

Aims for the first-line setting where Merck's Keytruda dominates

- PMLiVE

Merck chases Roche with triple-negative breast cancer data for Keytruda

Data demonstrated a delay in disease progression or death

- PMLiVE

Onyx Health receive national recognition as a “one to watch” business in Newcastle

Specialist marketing communications agency Onyx Health have been nationally recognised by The Sunday Times as one of six “one to watch” businesses based in Newcastle.

Onyx Health

- PMLiVE

Double blow to amyloid drug hopes as Roche, Lilly trial fails

The two investigational candidates were unable to show benefit

Onyx Health Launch ‘Game-changing’ New Digital Offer

Onyx Health have recently launched a new digital offering to bridge the digital skills gap in the pharma and healthcare sectors

Onyx Health

- PMLiVE

Roche posts minor sales miss in Q4 as biosimilar pressure grows

Swiss pharma still managed an 8% increase in pharma sales

Roche Basel Switzerland

Roche files Tecentriq/Avastin combo in liver cancer

First treatment in over a decade to improve overall survival

- PMLiVE

EU grants conditional approval to Roche’s lymphoma drug Polivy

Drug demonstrated a 40% complete response rate in trial

Roche Basel Switzerland

Roche and Illumina partner on genomics for cancer diagnostics

Will leverage genomics system to match optimal cancer treatment

- PMLiVE

EU, US biotechs merge to create fibrosis, cancer player

New company will be headquartered in Copenhagen, Denmark

- PMLiVE

NICE knocks back Roche’s Tecentriq for small cell lung cancer

Insufficient evidence to approve use in SCLC on the NHS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links